Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024GlobeNewsWire • 09/05/24
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/08/24
Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewsWire • 07/25/24
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial ProductBenzinga • 06/27/24
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona StocksInvestors Business Daily • 06/13/24
Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/09/24
Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERSGlobeNewsWire • 05/09/24
Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024GlobeNewsWire • 05/02/24
Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate UpdateGlobeNewsWire • 04/25/24